Abstract:Cannabidiol (CBD) shows great anti-inflammatory potential; however, the hydrophobicity and strong first-pass effect of CBD leads to its extremely low oral bioavailability. Poloxamer 407 (P407) is a triblock copolymer composed of (poly)ethylene oxide (PEO) and (poly)propylene oxide (PPO) sections. It has a PEO-PPO-PEO structure, which is widely used in the preparation of drug delivery systems that are highly biocompatible. When it reaches a certain concentration in water, P407 can self-assemble into a micelle structure containing a hydrophobic core and a hydrophilic shell. A potential approach to enhancing the oral bioavailability of hydrophobic drugs incorporating them into the hydrophilic carrier. We prepared CBD nanomicelles with a drug loading of 14.29% by a cosolvent evaporation method using P407 with appropriate antioxidants. Cell experiments indicated that anti-inflammatory markers (IL-4 and IL-10) increased, while inflammatory markers (TNF-α and IL-6) decreased. Moreover, animal experiments showed that inflammatory cells were inhibited by CBD nanomicelles, and the anti-inflammatory effect of micelles was better than that of CBD, while no obvious evidence indicated toxicity to the liver and kidney.

Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy